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Background: Epithelioid hemangioma (EH) of bone is a vascular neoplasm 
with a ubiquitous distribution, including bone and soft tissue. The clinical 
behavior of EH is complicated because of its multifocal presentation and rare 
lymph node involvement. To date, up to 25% EH of bone presents 
synchronous bone lesions and specific gene alterations. Recently, a novel and 
recurrent FOS gene rearrangement was present in nearly one third of EH 
across a variety of locations. Before the discovery of gene rearrangements 
specific to this rare entity, EH was often misdiagnosed as epithelioid 
hemangioendothelioma (EHE) or angiosarcoma. Acute Myeloid Leukemia 
(AML) is characterized by an increase in the number of myeloid cells in the 
bone marrow and an arrest in their maturation, frequently resulting in impaired 
hematopoietic differentiation that results in granulocytopenia, 
thrombocytopenia or anemia, with or without leukocytosis. Currently, 
Azacitidine is the first-line clinical drug for both MDS and AML, whereas 
Venetoclax is mainly used for chronic lymphocytic leukemia (CLL) patients 
with or without 17p deletion. The combination of Venetoclax with Azacitidine is 
being tested with positive clinical results in AML therapy. However, the 
molecular mechanisms underlying the effect of this combination therapy are 
still unclear. Therefore, in this study we analyzed the molecular effects of 
Azacitidine and Venetoclax combination on the nuclear inositide-dependent 
pathways, mainly focus on PLC-β1. 
Aim: This study aimed at describing for the first time a metachronous 
multifocal lesions case of EH with fatal outcome and analyze the role of 
inositide pathways in AML.  
Results: Here we reported the first case of EH with multifocal metachronous 
bone lesions. This case shows the possible existence of multifocal 
metachronous EH without producing a fatal outcome. FOS gene 
rearrangement is critical to assistant the diagnosis of EH. On the other hand, 
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we studied inositide signalling in AML, confirming the IC50 of MOLM-13, HL-60, 
THP-1 and U-937 hematopoietic cell lines when exposed to Azacitidine and 
Venetoclax. Moreover, Azacitidine and Venetoclax treatment could induce an 
increase of the Sub-G0/G1 phase, as well as a G0/G1 arrest in MOLM-13 cells 
and HL-60 cells. At the same time, it seems to prolong the S phase in U-937 
cells. Furthermore, the combination therapy was also able to specifically induce 
myelopoiesis, as MOLM-13 and THP-1 cells showed an increased expression 
of CD14. Finally, the combined treatment triggers a higher expression of 















1.1. Epithelioid hemangioma (EH) and endothelial cells 
Epithelioid hemangioma (EH) of bone is a vascular neoplasm with a ubiquitous 
distribution, including bone and soft tissue [1]. World Health Organization 
(WHO) defines EH as a locally aggressive bone neoplasm with no connotation 
of it being a benign or intermediate tumor [2], indicating a controversial 
definition of EH. The clinical behavior of EH is complicated because of its 
multifocal presentation and rare lymph node involvement [1, 3–6]. EH could be 
aggressive locally with a recurrence in 11% of cases [7]. These manifestations 
of the tumor lead to diagnostic difficulties since EH lacks characteristic 
radiological features [3]. 
To date, up to 25% EH of bone presents synchronous bone lesions and 
specific gene alterations. Recently, a novel and recurrent FOS gene 
rearrangement was present in nearly one third of EH across a variety of 
locations [8–10]. Another recurrent ZFP36-FOSB fusion has been reported in 
a small subset of EH with atypical morphological features that do not reveal 
FOS gene rearrangement [1]. Before the discovery of gene rearrangements 
specific to this rare entity, EH was often misdiagnosed as epithelioid 
hemangioendothelioma (EHE) [11] or angiosarcoma [12]. 
Morphologically, EH exhibits distinctive well-formed vascular channels 
composed of cells that have an endothelial phenotype and epithelioid 
morphology [1, 8, 10]. The epithelioid endothelial cells that protrude into the 
vascular lumen create a characteristic cobblestone or tombstone appearance. 
It is consistent to observe chronic inflammatory cell infiltration, including plasma 
cells and eosinophils. EH has a diverse range of microscopic features, 
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depending on the composition and distribution of the vascular and inflammatory 
cellular components. In literature, EH is characterized by an inflammatory 
angiomatous nodule or an atypical or pseudo pyogenic granuloma or a 
histiocytoid hemangioma [13–15], when infiltration of various inflammatory cells 
is predominant, cobblestone-like endothelial cells are conspicuous. 
Interestingly, it has been recently shown that endothelial cells are capable of 
undergoing endothelial to mesenchymal transition, a newly recognized type of 
cellular trans-differentiation in which endothelial cells adopt a mesenchymal 
phenotype displaying typical mesenchymal cell morphology and functions, 
including the acquisition of cellular motility and contractile properties [16]. 
1.2. Mesenchymal stem cells (MSCs) 
Mesenchymal stem cells (MSCs), also referred to as multipotent mesenchymal 
stromal cells, have been studied since the 1950s [17, 18]. Peculiar 
characteristics of the MSCs are not only the ability of self-renewal, but they can 
also be induced in vitro and in vivo to differentiate into endothelial cells, 
adipocytes, chondrocytes and osteocytes, which all comprise the 
mesenchyme [19] (Figure 1). Because of that, MSCs are an extraordinary 
model to investigate the biological mechanisms that allow a cellular population 
to generate diverse cell types as a potential tool in cellular therapies for several 
clinical applications. Moreover, MSCs exist in almost all tissues, including 
bone marrow (BM) [20], adipose tissue [21], skeletal muscle [22], dental pulp 
[23] and endometrium [24]. In BM, MSCs coexist with hematopoietic stem cells 




Figure 1. Multipower of MSCs. MSCs can differentiate into endothelial cells, 
osteocytes, chondrocytes, myocytes, adipocytes [19]. 
1.3. Therapeutic potential of MSCs 
1.3.1. Role of MSCs in bone and tissue repair 
Bone defects frequently accompany recovery from trauma, revision 
arthroplasty, or tumor resection surgeries. Autologous bone grafting 
represents the gold standard therapeutic strategy, despite its many 
drawbacks, including: (1) the limited supply of autologous bone, (2) increased 
operation time and blood loss, (3) temporary disruption of bone structure in the 
donor site, and (4) donor site morbidity [25]. Allografting carries a risk of 
disease and/or infection [26]. Therefore, MSC-based bone regeneration is 
considered an optimal approach [27]. The MSC osteoblast-differentiation 
capacity has been studied, and BM-derived MSCs represent the most 
frequently applied cells for osteoblast differentiation [28, 29]. However, given 
the low frequency of MSCs in the BM of a healthy adult (0.001 - 0.01%), many 
authors believe that it is necessary to expand the cells ex vivo to obtain a 
larger number of cells available for the repair of large bone defects [30]. 
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Osteogenic differentiation of MSCs is a complex process due to several 
stimulating factors that play important roles. Among them, the most used one 
for in vitro and ex vivo osteogenesis is BMP-2, which is expressed during 
osteogenesis and is usually immobilized on scaffolds to promote osteoblast 
differentiation [31–33]. Apart from BMP-2, also BMP-7 and BMP-9, all 
belonging to the same family, can regulate osteogenesis via activation of 
TGF-β/SMAD and Wnt signaling pathways, respectively [34, 35]. 
Studies on MSC-based cell therapy for bone defects and the use of novel 
scaffolds inspired advances in vitro and in vivo [36, 37]. Clinical applications of 
MSCs in bone reconstruction are widely described, including implantation of 
scaffolds seeded with MSCs into bone defect sites. Specifically, dentists have 
used this technique to address alveolar cleft defects, jaw defect reconstruction, 
and maxillary sinus augmentation, with excellent clinical prognosis [38, 39]. 
MSCs are also studied for other applications, such as tendon injury, which is a 
common problem associated with sport but, at present, with few effective 
scientifically proven treatments [40]. The literature of the last decade about in 
vivo studies on tendon healing shows that MSCs can be harvested from 
different tissues to be clinically applied. Moreover, MSCs clinical applications 
can be effective in inducing specific signaling pathways, as BMP-14 induces 
myogenic differentiation of bone-marrow MSCs via the Janus N-terminal 
kinase (JNK)/SMAD1-peroxisome proliferator-activated receptor-signaling 
pathway [41]. Studies describing tendogenic differentiation of MSCs were not 
only limited to stimulating factors and scaffolds but they also referred to 
mechanical stimuli that play essential roles in MSC differentiation into tendon 
lineages [42, 43].  
1.3.2. Role of MSCs in angiogenesis 
Angiogenesis is the formation of new capillaries from pre-existing vessels and 
consists of stimulation, migration and proliferation of endothelial cells, 
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extracellular matrix (ECM) degradation and capillary tube formation [44]. 
MSCs are good candidates to augment or inhibit angiogenesis due to their 
pro/anti-angiogenic properties and great potency of expansion. MSCs can 
enhance angiogenesis and vascular integrity by increasing a lot of 
angiogenetic molecules, such as angiopoietin-1 (Ang1), Tie2 (Ang-1 receptor), 
vascular endothelial growth factor (VEGF)/vascular endothelial growth factor 
receptor 2 (VEGFR2), which can protect MSCs and endothelial cells by 
modulating apoptosis, via increase of Bcl-2:Bax ratio and decrease of 
Caspase-9 and -3 activation [45, 46]. In this way, proliferation and migration of 
endothelial cells is favored, thus contributing to the recruitment of endothelial 
progenitor cells into newly sprouting blood vessels [47, 48].  
Moreover, MSCs have the potential for trans-differentiation into endothelial-like 
cells in both in vivo and in vitro [49, 50], which leads to employing MSCs as a 
resource of endothelial cells, providing novel therapeutic potential on 
neoangiogenesis [51]. The endothelial differentiation of MSCs involves 
concomitant changes in the expression of endothelial-specific genes, including 
kinase insert domain receptor (KDR), Fms-related tyrosine kinase-1 (FLT-1), 
VEGFR-1 and VEGFR-2 [52, 53]. In addition, extracellular mechanical 
properties influence the trans-differentiation of MSCs through an interaction 
between ECM proteins and MSC surface receptors, thereby inducing 
mechano-transduction signaling pathways in MSCs [54]. In return, endothelial 
cells could initiate MSC differentiation into endothelial-like cells by producing 
Nitric oxide (NO) [55]. 
Until now the effect of MSCs on tumor growth and angiogenesis remains 
strongly controversial [56]. However, novel properties of MSCs as 
anti-angiogenic/cytotoxic agents, that eliminate capillary formation, have been 
observed and are thought to be mediated by cell-cell contact or paracrine 
signaling [57, 58], which is particularly important in tumor progression. 
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Moreover, some reactive oxygen species (ROS) were produced when MSCs 
migrated toward endothelial cells-derived capillaries in Matrigel, which finally 
can lead to endothelial cell apoptosis [57].  
1.3.3. MSCs and hematopoiesis 
Friedenstein et al. firstly reported the formation of heterotopic ossicles 
containing bone and hematopoietic tissue, upon heterotopic CFU-F 
transplantation in semi-syngeneic animals, revealing the evidence of a critical 
role for BM stromal progenitors in supporting hematopoiesis [59]. Until now, 
the exact mechanism of how MSCs support hematopoiesis is not fully 
understood. In some animal experiments, after lethal whole-body irradiation, 
supplementation with HSCs and simultaneous injection of donor 
MSCs/marrow stromal cells can accelerate the recovery of hematopoiesis [60, 
61]. Similar results could be found in another study showing that bone marrow 
stromal cells could maintain hematopoiesis in vitro for more than 6 months 
[62]. More recently, a rare subset of MSCs was observed around blood 
vessels and this harbored the neuroctoderm stem cell marker nestin in murine 
bone marrow [63]. These cells were spatially associated with HSCs and 
expressed high levels genes which could maintain HSC, such as CXCL12, 
angiopoietin-1, c-kit ligand, vascular cell adhesion molecule-1, interleukin-7 
and osteopontin [63]. Irrespective of the underlying mechanisms, accumulating 
evidence suggests that bone marrow MSCs may promote HSC engraftment 
and repopulation, with co-transplantation of human HSCs and MSCs resulting 
in increased chimerism and/or hematopoietic recovery in both animal models 
and humans [64–66]. 
Human bone marrow MSCs were also found to significantly increase the 
proportion of asymmetrically dividing CD34+ CD133+ human hematopoietic 
progenitors mediated by Integrin-β1 [67]. Furthermore, MSCs are linked with 
megakaryocyte differentiation, pro-platelet formation and platelet release [68], 
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and they also support B-lymphocyte development upon appropriate co-culture 
with cord-blood CD34+ cells [69]. Interestingly, it is suspected that the 
osteoblastic cells deriving from MSCs may also have a critical role in the 
regulation of primitive hematopoietic cells [70, 71]. 
1.4. Acute myeloid leukemia (AML) 
1.4.1. Epidemiology, etiology, Clinical features, and prognosis 
AML is characterized by an increase in the number of myeloid cells in the BM 
and an arrest in their maturation, frequently resulting in impaired hematopoietic 
differentiation that results in granulocytopenia, thrombocytopenia or anemia, 
with or without leukocytosis [72]. Epidemiologically, AML is a cancer whose 
incidence increases with age. In fact, AML accounts for about 90% of all acute 
leukemias in adults, but it is less frequent in children [73].  
The clinical signs and symptoms of AML are vague and non-specific, 
particularly in the early stage. Somehow, they are usually directly attributable 
to the leukemic infiltration of the BM, leading to cytopenia. Most signs and 
symptoms of AML are caused by the replacement of normal blood cells with 
leukemic cells. Typically, patients show signs and symptoms of fatigue, 
hemorrhage, or infections and fever. Also, it is common to present pallor, 
fatigue, and dyspnea on exertion [74]. Leukemic infiltration of various tissues, 
including the liver, spleen, skin, lymph nodes, bone, gum tissue, and central 
nervous system, can produce a variety of other symptoms.  
The chance of AML therapy success depends on several factors. Prognostic 
factors can be divided into those that are related to the patient and those that 
are related to the disease. Patient-associated factors (e.g., increasing age, 
coexisting conditions, and poor performance status) commonly predict 
treatment-related early death, whereas disease-related factors (e.g., white-cell 
count, prior myelodysplastic syndromes (MDS) or cytotoxic therapy for another 
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disorder, and leukemic-cell genetic changes) predict resistance to current 
standard therapy [75]. 
1.4.2. Pathophysiology and molecular characteristics 
Regardless of its etiology, the pathogenesis of AML involves the abnormal 
proliferation and differentiation of a clonal population of myeloid stem cells. 
Well-characterized chromosomal translocations could lead to the formation of 
chimeric proteins, which alter the normal maturation process of myeloid 
precursor cells. For example, the presence of a t(8;21) translocation is 
associated with leukemic stem cell formation, as it interferes with 
hematopoietic differentiation and enhances the self-renewal capacity of 
hematopoietic cells. Apart from chromosomal rearrangements, also molecular 
mutations have been implicated in the development of AML. In fact, genetic 
mutations are identified in more than 97% of cases [76], often in the absence 
of any large chromosomal abnormality [77]. Alterations of genes involved in 
epigenetic regulation (DNMT3A, IDH1 AND IDH2) have downstream effects on 
both cellular differentiation and proliferation in more than 40% of AML cases 
[77]. 
1.4.3. Therapies 
The general therapeutic strategy in patients with AML has not changed 
substantially in more than 30 years [78].  
The first important and curative treatment in AML is allogeneic hematopoietic 
stem cell transplantation (HSCT). The major lethal complication of HSCT is 
graft-versus-host disease (GVHD), an immunological disorder in which 
immune cells from the donor attack healthy recipient tissues, including the 
gastrointestinal tract, liver, skin, and lungs [79]. GVHD may manifest as acute 
(aGVHD) or chronic (cGVHD) and is still an obstacle that limits the 
effectiveness of this therapy, occurring in more than 50% of patients 
13 
 
undergoing HSCT [80]. The exact pathophysiology of GVHD is not completely 
known, although some studies demonstrated that MSCs play an active role in 
promoting facilitation of HSC engraftment after transplantation, because they 
are part of the BM niche, where they support hematopoiesis [81, 82]. 
Therefore, as a novel cell-based therapeutic approach, based on MSCs, it is 
now promising [83]. 
Another common treatment for AML patients consists primarily of 
chemotherapy and is divided into three phases: induction, consolidation, and 
post-remission. Initial assessment is essential to determine whether a patient 
is eligible for this type of intensive chemotherapy, that aims to induce a clinical 
promising response. Then, after a complete remission is achieved, appropriate 
post-remission therapy is essential to eliminate any residual undetectable 
disease [75]. 
1.4.3.1. Azacitidine 
Azacitidine is a cytidine analog in which the carbon atom at position 5 in the 
pyrimidine ring has been replaced by a nitrogen atom, which allows its 
incorporation into nucleic acids (Figure 2). Azacitidine can be phosphorylated 
by uridine-cytidine kinase to a monophosphate derivative and then further to 
diphosphate and triphosphate forms, which are incorporated into RNA, with 
consequent disruption of mRNA and protein synthesis [84–87]. 
In the early times, the main anti-neoplastic activity of azacitidine was thought 
to interference with nucleic acid metabolism. Further investigations showed 
that azacitidine had additional anti-tumor effects, most notably linked to DNA 
hypermethylation, tumor suppressor gene silencing and disruption of myeloid 
maturation and differentiation [88]. 
Azacitidine has been the first drug approved by the US Food and Drug 
Administration (FDA) for the treatment of MDS [89] and, currently, it has 
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regulatory approval for the treatment of both MDS and AML with 20–30% BM 
blasts in the US, Canada, and the European Union (EU). Many studies 
showed that azacitidine is much more efficient in hematologic malignancies 
than in solid tumors, although it can function only after a certain number of 
cycles and with continuous therapy over time. This is due to the fact that 
azacitidine effects are much more marked in the S-phase and in rapidly 
dividing cells [88, 90–92]. 
 
Figure 2 Molecule structure of Azacitidine 
1.4.3.2. Venetoclax 
Venetoclax (ABT-199, GDC-0199, Venclexta™) is a small-molecule and highly 
selective orally bio-available anticancer drug that targets B-cell cancers, 
specifically the BH3 domain of BCL-2 (Figure 3) [93]. As a BH3 mimetic, 
Venetoclax displays high affinity to the BH3-binding groove of BCL-2 and is 
able to displace pro-apoptotic BH3-only proteins (e.g. BIM) bound to BCL-2. 
Consequently, free BH3- only proteins can activate apoptotic effectors (BAX 
and BAK) or inhibit other anti-apoptotic members (MCL-1). Thus, Venetoclax 
triggers and restores apoptosis in tumor cells by releasing pro-apoptotic 




Figure 3. Molecular structure of Venetoclax 
Venetoclax was granted accelerated approval by FDA for chronic lymphocytic 
leukemia (CLL) with 17p deletion in April 2016 and was later approved in June 
2018 for CLL with or without 17p deletion [95]. Currently, it is also used as part 
of a combination therapy for AML, as the AML therapy with single agent 
Venetoclax showed limited anti-leukemic activity in a number of patients, and 
was associated with low response rates and short response duration in those 
refractory/relapsed cases [96]. Clinical studies have shown that combination of 
Venetoclax with HMA agents, such as azacitidine, decitabine or with low dose 
cytarabine, demonstrates higher response rates, durable responses and a 
longer overall survival in elderly AML adults refractory to other treatments, and 
this combination treatment has been approved by FDA in adults aged 75 years 
or above diagnosed with these refractory AML [97–102]. Additionally, two 
other combination therapies (Venetoclax 400 mg in combination with 
azacitidine, trial NCT02993523; and Venetoclax 600 mg in combination with 
low dose cytarabine, trial NCT03069352) are currently undergoing definitive 
randomized Phase III studies for newly diagnosed AML in elderly patients unfit 
for intensive therapies, with overall survival as a primary objective. 




Phosphoinositides (PIs) are inositol phospholipids constituted by hydrophilic 
inositol groups linked to two fatty chains. PIs represent the most frequently 
studied phospholipids. They are composed of the precursor 




Figure 4. structure of Phosphoinositides [104] 
PIs play several pivotal roles in cell proliferation, cell differentiation and gene 
expression. The kinases and phosphatases related to the PI pool are present 
at both the plasma membrane and nuclear level, where they localize in specific 
distinct compartments, like the nuclear speckles [105].  
1.5.2. Phosphoinositide-specific Phospholipases  
Phosphoinositide-specific Phospholipases (PLCs) are a group of 
inositide-dependent enzymes that cleave phosphatidylinositol 
4,5-bisphosphate [PtdIns(4,5)P2] to inositol 1,4,5-trisphophate (IP3) and 
diacylglycerol (DAG). These are key second messengers that modulate cell 
proliferation, cell apoptosis, activation of immune cells and stem cell 
differentiation via intracellular release of calcium ions and activation of Protein 
Kinase C (PKC), respectively [106, 107] (Figure 5). Several PLC isoforms are 
also found in the nucleus, together with their substrates [108–110].  
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Until now 13 mammalian PLC isozymes have been identified and they are 
divided into 6 subfamilies (β, γ, ε, δ, ζ, η). Interestingly, all PLC isozymes show 
highly conserved domains (X and Y) as well as unique mingled domains (C2 
domain, the EF-hand motif, and the pleckstrin homology domain) [111]. 
Because of that, each isoform has a proper regulation, function, and tissue 
distribution [106]. For example, PLC-ζ is associated with nuclear infertility 
mechanisms in relation to oocyte activation [112] while PLC-γ is critical in cell 
migration and invasion [113]. Moreover, PLC-ε is specifically linked to 
colorectal cancer suppression [114]. 
Among these isoforms, PLC-β1 plays an important role in cell cycle control at 
both G1/S transition, via interaction with its downstream target cyclin D3, and 
G2/M progression, through different molecules [105]. A recent study 
demonstrated its critical role in osteogenic, myogenic, and adipogenic 
differentiation processes [115]. Moreover, PLC-β1 is also associated with 
proliferation and differentiation of hematological malignancies, such as MDS 
and AML [116, 117]. Despite from this, PLC-β1 is also linked with brain 
disorders, due to its cell cycle regulation in central nervous system pathologies 




Figure 5. PLC-β signaling [120] 
 
1.5.3. Role of nuclear PLC-β1 in osteogenic and adipogenic differentiation 
Osteogenic differentiation is stimulated by several signaling pathways, mainly 
controlled by BMPs, Osterix (Osx/Sp7), and Runt-related transcription factor 2 
(Runx2). The increase of nuclear PLC-β1 expression can regulate osteogenic 
differentiation of C2C12 cells in response to BMP-2 stimulation [115]. PLC-β1 
plays a role also in the osteogenic differentiation of MSCs, as it decreases 
during the early stages of MSC osteogenic differentiation and increases with 
cell growth [121]. Interestingly, along with PLC-β1, also cyclin E displays a 
constitutively high expression level in proliferating MSCs. This may suggest 
that the two proteins co-immunoprecipitate, hence they physically interact. 
However, the exact mechanisms of PLC-β1 role in osteogenic cell proliferation 
and differentiation is still missing. Nuclear PLC-β1 can also be involved in 
adipocyte differentiation. Indeed, during the in vitro differentiation of 3T3-L1 
adipocytes, regulated by PKCα pathways, PLC-β1 expression increases [122]. 
Interestingly, the overexpression of PLC-β1 mutants, lacking the nuclear 
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localization sequence, showed that nuclear PLC-β1 is highly expressed in two 
distinct moments, both essential for an effective differentiation. [123].  
1.5.4. Role of nuclear PLC-β1 in hematopoietic cell cycle and differentiation 
Nuclear PLC-β1 plays a critical role in cell cycle control at both G1/S transition 
and G2/M progression in hematopoietic cell lines, depending on the 
experimental model. For example, in HL-60 human promyelocytic leukemia 
cells, PLC-β1 expression reaches its peak at the late G1 phase and at G2/M 
transition for cell cycle progression. In contrast, in K562 human 
erythroleukemia cells, PLC-β1 overexpression is associated with a prolonged 
S phase of the cell cycle and a delay in cell proliferation [124, 125]. Moreover, 
it has been observed an increase of PLC-β1 expression in MDS cells during 
the myeloid differentiation induced by hypomethylating therapies, suggesting 
that PLC-β1 is a key molecule in MDS hematopoietic regulation [126].  
PLC-β1 catalyzes the reaction that cleaves PtdIns(4,5)P2 to produce IP3 and 
DAG. Downstream PI(4,5)P2 there are other enzymes, called Dyacylglycerol 
kinases (DGKs), that phosphorylate DAG and lead to the synthesis of 
Phosphatidic Acid [127]. DGKs are a family of 10 proteins divided into 5 
classes based on their specific domain composition. One of the DGK 
isoenzymes is DGKα, which is strongly localized inside the nucleus in K562 
cells, showing a slight activation peak at G2/M phase. In these cells, the 
inhibition or silencing of DGKα resulted in a block at the G0/G1 checkpoint and 
a reduction of S and G2/M cell cycle phases without significant autophagy or 
apoptosis. Instead, the overexpression of DGKα is high at the S phase, 
indicating that DGKα plays a positive role in G1/s transition cell cycle of 
leukemia cells [128, 129].  
1.5.5. PI3K/Akt/mTOR signalling pathway and leukemogenesis 
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The phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling pathway plays 
an important role in the control of several cellular processes, such as cell 
growth, proliferation, survival, and neoplastic transformation [130, 131]. 
Several stimuli, including a range of growth factors and mitogens, activate cell 
surface tyrosine kinase receptors, which in turn determine the activation of 
PI3K.  
PI3K is a serine/threonine kinase that phosphorylates PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3 which, in turn, can be a docking site for other downstream 
proteins, such as Akt [132]. Negative regulation could be mediated by the 
PTEN phosphatase, that leads to deactivation of Akt. In particular, PTEN 
converts PtdIns(3,4,5)P3 into PtdIns(4,5)P2, directly reversing the effects of 
PI3K. Following Akt activation, also phosphorylated mammalian Target of 
Rapamycin (mTOR) can activate specific downstream pathways, in order to 
regulate DNA repair and transcription, RNA dynamics and protein synthesis. 
The structure of mTOR is peculiar, as it is constituted by two molecular 
complexes: mTORC1 and mTORC2, which must be phosphorylated to be 
activated. Phosphorylated mTORC2 can activate other downstream targets to 
induce a negative feedback activation of Akt, thus triggering a feedback loop 
on cell growth and protein synthesis [133, 134]. On the other hand, mTORC1 
is mostly associated with autophagy [135], which can be induced by increased 
elevated intracellular levels of ROS.  
The PI3K/Akt/mTOR pathway is closely linked with hematological 
malignancies. Mutations of PI3K and/or Akt genes and their related molecular 
targets are detected in more than 60% de novo AML cases, as well as some 
other lymphoid malignancies. In fact, PTEN is frequently mutated in T-Acute 
Lymphoblastic Leukemia (T-ALL), leading to hyperactivation of the pathway 
[136] . Finally, another frequent mutated gene in hematological malignancies is 
Notch-1, which could be observed in more than 50% of the T-ALL patients and 
is correlated with PI3K. In fact, Notch-1 activates the Notch signaling pathway, 
triggering the upregulation of PI3K/Akt pathway through the transcription factor 
HES1 that inhibits the expression of PTEN.  
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2. AIM OF WORK 
Here we described the first case of EH with multifocal metachronous bone 
lesions, showing for the first time the pathologic and radiologic findings of a 
non fatal case. As endothelial cells are capable of undergoing endothelial to 
mesenchymal transition, we then moved towards AML studies, to better focus 
on the molecular relevance of signal transduction pathways in another 
experimental model. We studies the effect of Azacitidine in combination with 
Venetoclax in AML, including several aspects: 
1. cell cycle regulation 
2. hematopoietic differentiation 
3. phosphoinositide signaling pathways 
 
 
3. MATERIALS AND METHODS  
3.1. EH patient characteristics 
A 20-year-old Caucasian female with no history of major illness was admitted 
in 2001 at the Istituto Ortopedico Rizzoli, Bologna, Italy, where all the tissues 
and radiographic pathologic data were collected during the following 17 years. 
Since she was diagnosed with EH of bone in the beginning, she entered in a 
clinical trial approved by the independent ethics committee of the Istituto 
Ortopedico Rizzoli, which was registered as n. NCT03169595 at 
ClinicalTrials.gov.  
3.2. Immunohistochemistry (IHC) 
The osteolytic lesion in the right distal humerus was extracted, and 
paraffin-embedded tissue sections were prepared and stained with ERG, 
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CD31, FOSB, CAMTA1, TFE3, and AE1/3 antibodies. For each stain, a known 
positive case was used as a positive control. Negative controls were 
concurrently run, with the primary antibody replaced with buffer.  
Mouse monoclonal anti-ERG antibody to the N-terminus (9FY-clone, BioCare 
Medical, Concord, California, USA) was used at 1:50 dilution (Dako 
Autostainer), whereas polyclonal CAMTA1 staining was performed at 1:1000 
dilution (Atlas Antibodies, Stockholm, Sweden). Paraffin-embedded slides 
were loaded into a PT Link module (Dako, Carpinteria, CA) and subjected to 
an antigen retrieval/dewaxing protocol with EnVision FLEX Target Retrieval 
Solution (Dako) with EDTA at a high pH (pH 9.0), using an electric pressure 
cooker for 3 min at 12–15 pounds per square inch (120°C), and cooled for 10 
min prior to immunostaining. 
CD31 (7C70A clone, Dako) antibody was diluted at 1:80; AE1/3 (AE1/AE3 
clone, Dako, Carpinteria, California, USA) at 1:100; FOSB (5G4 clone, Cell 
Signaling Technology, Danvers, MA) at 1:100; TFE3 (EPR11591 clone, 
Abcam, Cambridge, UK) at 1:100. All these stains were carried out on the 
Leica Bond Max III automated system (Bond, Bannockburn, Illinois). Antigen 
retrieval was performed on the instrument at pH 6.0 with citrate buffer. The 
Bond Polymer Refine Detection Kit (Leica Microsystems, Bannockburn, 
Illinois, USA) was the detection method, which was used according to the 
manufacturer’s instructions, with diaminobenzidine as the chromogen (brown 
chromogen), and hematoxylin as counterstain. Immunoreactivity was 
assessed only if the tumor cells showed nuclear staining, according to the 
percentage of positive tumor cells approximately within a range of 10 %.  
3.3. Hematopoietic Cell Lines and Treatments 
Human HL-60 promyelocytic, MOLM-13 acute myeloid leukemia (AML 
secondary to MDS), THP-1 acute myeloid leukemia and U-937 histiocytic 
lymphoma cell lines were cultivated at 37°C with 5% CO2 in RPMI 1640 
medium (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% 
heat-inactivated fetal bovine serum at an optimal cell density of 0.3-0.8 x 106 
cells/mL. Cells were treated with different concentration of Azacitidine and 
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Venetoclax, alone or in combination for 24 hours, in order to give cells a 
concentration comparable to the plasma concentration reached in current 
clinical applications. 
3.4. MTT proliferation assay 
Hematopoietic cell proliferation was analyzed by a colorimetric method using 
the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA) following the manufacturer’s instructions. 1x106 Cells were 
seeded in 96-well plates and treated for 24 hours with Azacitidine and 
Venetoclax of different concentrations respectively, and different combinations 
of both. The absorbance values were recorded at 450 nm after reagent 
incubation at 37°C for 3 hours and corrected by subtracting the background 
absorbance (culture media alone). All samples and controls were run in 
triplicate and experiments were repeated at least three times.  
3.5. Flow cytometric analysis of cell cycle 
0.5x106 cells of each cell line were fixed in 70% cold ethanol at -20°C 
overnight. Cells were washed twice with PBS and then resuspended in PBS 
1X containing 40 μg/ml of PI (propidium iodide) and analyzed by FACS ( 
Beckman Coulter), as reported elsewhere [137]. 
3.6. RNA extraction and reverse transcription 
Total RNA was isolated from cell lines by using the RNeasy Mini Kit (Qiagen 
Ltd, Valencia, CA, USA) according to the manufacturer’s protocol, the of the 
extracted RNA were subsequently assessed by measuring its absorbance at 
260 and 280 nm using the NanoDrop spectrophotometer. 
The reverse transcription of the extracted RNA was then performed into cDNA, 
following the protocol and reagents provided by the Applied Biosystems® 
High-Capacity cDNA Reverse Transcription kit. 
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3.7. Real-time PCR 
Variations in gene expression were evaluated by Real Time PCR with TaqMan 
probes (Tema Ricerca) and TaqMan gene expression Mastermix (4369016, 
Applied Biosystem). 10ng cDNA of each sample were loaded, and the 
measurement was performed by the ABI Prism 7300 SDS instrument. Data 
analysis was done by the 2-Ct method, considering GAPDH as housekeeping 
gene. Each sample were duplicated, and all these experiments were repeated 
twice. 
The probes used were: 




• Cyclin D3 
• Cyclin B1 
Genes involved in hematopoietic myeloid differentiation: 
• CD33 (myeloid hematopoietic progenitor) 
• CD11 (expressed by myeloblasts) 
• CD14 (expressed by monocytes) 
The statistical analysis was carried out with the application of the paired t-test, 
thanks to the use of the GraphPad Prism software. 
3.8. Western blotting 
3.8.1. Preparation of protein lysates 
Each hematopoietic cell line was collected and centrifuged 5 minutes at 1200 
rpm. Then, supernatant was discarded, and the pellet was washed in cold PBS 
1X. To obtain the protein lysate, cells were then resuspended in 100 μL of 
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Thermo Fisher Scientific® M-PER buffer, added with protease and 
phosphatase inhibitors. After that, samples were incubated for 30 minutes on 
ice and vortexed regularly every 5 minutes, before being sonicated for a cycle 
of 15 seconds at a strength of 40-50%. Finally, samples were centrifuged for 
10 minutes at 14.000 rpm at 4°C. For the quantification, samples were 
prepared in duplicate, along with a blank control and a standard BSA curve, 
using the Bradford dye. Sample reading was performed at 595 nm at the 
spectrophotometer. 
3.8.2. Electrophoretic run and saturation 
Samples were prepared in water in a final volume of 50 μL, with 40 μg of 
protein lysate, 5 μL of sample reducing agent 10X and 12.5 μL of LDS sample 
buffer 5X (all from Thermo Fisher Scientific®). Then, samples were incubated 
at 95° C for 5 minutes and subsequently loaded on a precast gel of 
polyacrylamide with a 4-12% gradient. After the run the membrane was 
specifically colored with red Ponceau, in order to highlight the bands and, after 
a cutting that divides the membrane according to the molecular weight of the 
target proteins, the membrane was washed in PBS 1X/TWEEN 0.1%. Then, 
the membrane was saturated for one hour with 5% milk and washed 
sequentially in PBS 1X/TWEEN 0,1% for 10 minutes. After this washing, 
specific primary antibodies were added and membranes were incubated at 
4°C with gentle, shaking overnight.  














Rabbit 150 kDa 
PLC-γ1 Santa Cruz Biotecnology 
® 
SC-7290 Mouse 155 kDa 
PKCα Invitrogen® PAS-1755 Rabbit 80 kDa 
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The antibodies were used after a 1:1000 dilution in BSA, milk or PBS tween. 
The day after, membranes were washed twice in PBS 1X/TWEEN 0.1% and 
incubated for 1 hour at room temperature with the appropriately prepared 
secondary antibodies of Thermo Fisher Scientific (mouse or rabbit, 0031460 
PA196832). After three washings in PBS 1X/TWEEN 0.1%, the membranes 
were treated with luminol Super Signal ™ West Pico Maximum Sensitivity 
Substrate and analyzed with the Bio-Rad ChemiDoc instrument. The ImageJ 
program was used for band quantification in relationship with housekeeping 
genes. The quantification of the phosphorylated forms of proteins was 
obtained by comparing the quantification obtained on the phosphorylated form 
(using the housekeeping gene) with that on the total form, to see the real 
changes after protein activation. 
3.9. Statistical Analyses 
Data are represented as mean ± s.e.m. and were analyzed by GraphPad 
Prism 5 software (GraphPad Software, La Jolla, CA, USA). Data analyses 
were performed using Student's t-test (two tailed) followed by Mann-Whitney 
unless otherwise stated. Data were considered significant at 95% confidence 
level. 
1 





Cst4059 Rabbit 57 kDa 








4.1 EH patient outcome 
The patient, a 20-year-old caucasian female with no history of major illness, 
was admitted with complaints of pain in the proximal humerus of the right arm 
in 2001. Radiographs revealed an expansile and osteolytic lesion of her right 
proximal humerus with focal cortical thinning and destruction (Figure 6). An 
incisional biopsy was performed, and the diagnosis was EHE, a low-grade 
malignant vascular tumor. Consequently, the patient received a massive bone 
allograft and plating construct after a resection of the right proximal humerus 
was performed. In the follow-up, no evidence of local recurrence and distant 
metastases were found in the next 13 years.  
  
Figure 6. a Tumor specimen radiograph showing an expansile lytic lesion of 
the proximal humerus extending into the metaphyseal region. b postoperative 
radiograph shows massive bone allograft replacement and plating. 
In 2014, the patient exhibited pain in her right elbow. Radiographs revealed a 
lytic and expansile intramedullary lesion of the proximal radius (Figure 7a). A 
bone scan displayed an increased uptake not only in the proximal radius but 
also in the left frontal skull (Figure 7b). On 1.5-T MRI a round lesion was 
observed in the frontal skull with a high signal on axial T1-weighted images 
and coronal T2-weighted images (Figure 7c and d). Since we assumed both 
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lesions were from the same origin, it was detrimental to obtain tissue from the 
lesion in the frontal skull. For this reason, the patient only underwent a trocar 
biopsy of the lesion in the right proximal radius. From this biopsy, the diagnosis 
of EHE was confirmed for the second time. The patient was then treated with a 
curettage of the lesion in the proximal radius, filling the bone cavity with 
cement and resection of the lesion in the skull. 
 
Figure 7. a Radiographs show a lytic and expansile intramedullary lesion of the 
proximal radius. b Bone scan shows an increased uptake in the proximal 
radius and the left frontal skull. c Axial T1-weighted post contrast enhanced 
MR image showing a lobulated extra-axial enhancing lesion from left frontal 
skull with hyperintensity. d Coronal T2-weighted image shows a small 
hyperintense extra-axial lesion of the left frontal region. 
At the follow-up in January 2018, 17 years after the initial diagnosis, 
radiographs showed another osteolytic lesion in the right distal humerus, distal 
to the initial lesion (Figure 8). Along with the lesions we observed in the last 
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follow-up, multifocal metachronous bone lesions in separate places was found. 
A trocar biopsy guided by computed tomography was performed for further 
pathologic test. The patient was presented alive without evidence of any 
EH-related fatal disease. 
 
Figure 8. 17 years after the initial diagnosis, radiograph shows new lytic lesion 
of the humeral diaphysis (arrow) distal to the initial lesion. 
4.2. IHC Lesion 
IHC on the patient’s specimens demonstrated that neoplastic cells were 
immunoreactive for specific endothelial markers ERG and CD31 but negative 
for cytokeratin AE1/AE3, which excluded the diagnosis of pseudomyogenic 
hemangioendothelioma. Also, tumor cells showed negative reaction with 
CAMTA1 and TFE3, which excluded the diagnosis of EHE. After excluding the 
diagnosis of EHE, molecular analysis was conducted to discover the new FOS 
rearrangement specific of EH on the above-mentioned specimens. However, 
immunohistochemical analysis showed that the neoplastic endothelial cells 
were strongly positive for FOSB antibody (Figure 9b). The 
immunohistochemical analysis was performed on the previous pathological 
tissues and the diagnosis of EH was confirmed in all specimens. Histologically, 
the neoplasm was characterized by a prominent proliferation of small, 
capillary-sized vessels, sometimes lacking a well-defined lumen associated 
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with areas of solid growth and increased cellularity (Figure 9a and c). The 
vessels were lined by epithelioid endothelial cells with an enlarged nucleus, 
with focal nuclear atypia and nuclear pleomorphism. Occasional eosinophils 
and lymphocytes were present in all samples.  
 
Figure 9. a Large epithelioid cell line well-formed vascular spaces (arrows) 
associated with isolated prevalent epithelioid or slightly spindled cells 
(asterisks) adjacent to a well-formed neoplastic vessel (haematoxylin and 
eosin; 400X magnification). b The neoplastic endothelial cells show a strong 
nuclear expression for FOSB antibody (400 X magnification). c Haematoxylin 
and eosin staining at a low power field (100 X magnification). 
4.3. Azacitidine and Venetoclax on hematopoietic cell lines 
4.3.1 Cell viability 
To determine the effect of Azacitidine and Venetoclax on cell viability, 4 cell 
lines (HL-60, MOLM-13, U-937, and THP-1) were treated with different 
concentration of these two drugs, alone or in combination, in vitro for 24h. 
Firstly, all cell lines were exposed to single agents to explore the IC50 of each 
treatment. As Figure 10 shows, both Azacitidine and Venetoclax showed a 
cytotoxic impact on all cell lines with a dose-dependent manner. Among them, 
Azacitidine showed an approximate 50% apoptosis rate at the dose of 7.5 μM 
in MOLM-13 cells, 10 μM in HL-60 cells, 20 μM in THP-1 cells and 10 μM in 
U-937 cells. On the other hand, Venetoclax inhibited cell proliferation in all cell 
lines tested, reaching an optimal 50% inhibition rate with 0.05 μM in MOLM-13 
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cells , 5 μM in HL-60 cells , 7.5 μM in THP-1 cells and U-937 cells (Figure 10). 
The result showed that HL-60 and MOLM-13 were relatively sensitive to 
Venetoclax, while U-937 is more Venetoclax-resistant than THP-1 cell lines.  
 
 
Figure 10. Azacitidine and Venetoclax inhibit the growth of leukemia cell lines. 
HL-60, U-937, THP-1, and MOLM-13 cells were exposed to different 
concentrations of Venetoclax for 24 h. Significant growth inhibition was 
observed in all leukemic lines following treatment with AZA at concentrations 
higher than 2.5 μM. Significant growth inhibition was also observed in 
MOLM-13 cells treated with Venetoclax at concentrations higher than 0.01 μM 
and in HL-60 cells were treated with Venetoclax at a concentration higher than 
1μM. At the same time, in U-937 cells and THP-1 cells, significant growth 
inhibition was observed when treated with Venetoclax at concentrations higher 
than 7.5 μM.  
In order to determine the synergistic effect of Azacitidine and Venetoclax on 
leukemia cell lines, 4 cell lines were exposed to different concentrations of the 
two drugs for 24h. For Venetoclax-sensitive cells, in order to reduce the 
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secondary cytotoxicity of Venetoclax, the concentration of 5 μM Azacitidine 
+2.5 μM Venetoclax in HL-60 cells was picked, while 5 μM Azacitidine +0.025 
μM Venetoclax in MOLM-13 cells was also chosen (Figure 11).  
 
Figure 11. Venetoclax-sensitive cells HL-60 and MOLM-13 were exposed in 
different combined concentration of Azacitidine and Venetoclax for 24h. 
For Venetoclax-resistant cells, THP-1 cells displayed the IC50 at the 
concentration of 12.5 μM Azacitidine +7 μM Venetoclax. In U-937 cells, in 
order to reduce the secondary cytotoxicity of Venetoclax, the concentration of 
7.5 μM Azacitidine +12 μM Venetoclax were picked. These combinations of all 
cell lines were selected for further assays.   
 
Figure 12. Venetoclax-resistant cells THP-1 cells and U-937 cells were 




4.3.2 cell cycle 
The Four cell lines were treated for 24h with in single or with specific combined 
concentrations of Azacitidine and / or Venetoclax and cell cycle was analyzed 
by flow cytometry. MOLM-13 cells showed a big fraction of sub-G0 phase with 
30.9% in Venetoclax-alone treatment group and 40.5% in combined treatment 
group. Similarly, HL-60 cells presented 17.9% apoptosis in Venetoclax-alone 
group while 33.1% in combined treatment group. Interestingly, an increased S 
phase could be observed in MOLM-13 cells, while in HL-60 cells an arrest in 
G0/G1 phase could be seen in the group treated with Azacitidine alone (Figure 
13). On the other hand, no significant difference in MOLM-13 cells were shown 
in cyclin B1 in corresponding with G2/M phase in flow cytometry. For HL-60 
cells, Cyclin B1 showed a decrease in all treatmented groups. In the 
meantime, real-time PCR showed that no significance of Cyclin D3 and Cyclin 
B1 in MOLM-13 cells whereas significant difference of cyclin molecules could 







Figure 13. Cell cycle and cyclin molecules were analyzed after treatment with 
Azacitidine and/or Venetoclax for 24h in MOLM-13 cells and HL-60 cells. A. 
Cell cycle analysis was performed by flow cytometry. B. the expression levels 
of the mRNA of cell cycle molecules were performed by Real-time PCR. 
Significance was obtained after multiple student’s t-test comparison. * = 
p-value < 0.05, ** = p-value < 0.01, ***= p-value < 0.001, **** = p-value < 
0.0001. 
For THP-1 cells, a G0/G1 arrest could be observed in all treated groups. For 
U-937 cells, both treatments showed a significant increase of S phase in both 
treatment groups, with 27.5% in Azacitidine, 38.2% in Venetoclax and 30.4% 
in the combined treatment, as compared with 24% of the control group. 
Real-time PCR showed that no significant difference of cyclin molecules in 
THP-1 cells while cyclin D3 was relatively highly expressed in the treated 







Figure 14. Cell cycle and relative cyclin molecules were analyzed after 
treatment with Azacitidine and/or Venetoclax for 24h in THP-1 cells and U-937 
cells. A. Cell cycle analysis was performed by flow cytometry. B. the 
expression levels of the mRNA of cell cycle molecules were performed by 
Real-time PCR. Significance was obtained after multiple student’s t-test 
comparison. * = p-value < 0.05, ** = p-value < 0.01, ***= p-value < 0.001, **** = 
p-value < 0.0001. 
4.3.3 differentiation 
CD33, CD11 and CD14 are some of the main differentiation markers on the 
surface of myeloid lineage cells [138–140]. CD11 is a myeloblast/granulocyte 
differentiate marker while CD14 is a specific differentiation marker for the 
monocyte/macrophage lineage.  
In MOLM-13 cells, CD14 showed a significant increase in all treated groups, 
whereas CD11 increased in the Venetoclax-alone treated group. In HL-60 
cells, CD11 increased in the Azacitidine-alone treated group (Figure 15). 
 
Figure 15. Cell differentiation molecules in MOLM-13 cells and HL-60 cells 
were analyzed by real-time PCR after treated by Azacitidine and/or Venetoclax 
for 24h. A. Significance was obtained after multiple student’s t-test 
comparison. * = p-value < 0.05, ** = p-value < 0.01, ***= p-value < 0.001, **** = 
p-value < 0.0001. 
In THP-1 cells, combined treatment showed a significant increase of CD14, 




Figure 16. Cell differentiation molecules in THP-1 cells and U-937 cells were 
analyzed by real-time PCR after treated by Azacitidine and/or Venetoclax for 
24h. A. Significance was obtained after multiple student’s t-test comparison. * 
= p-value < 0.05, ** = p-value < 0.01, ***= p-value < 0.001, **** = p-value < 
0.0001. 
4.3.4 inositide signaling 
In MOLM 13 cells, PLC-β1 showed an increase in the Azacitidine-alone 
treatment group and in the combined treatment group, while PLC-γ1 showed a 
significantly increase in the combined treatment group. On the contrary, PKCα 
showed a significant decrease in all treated groups, while p-Akt expression 
seems to be constant in all groups. In addition, BCL-2 decreased in 
Venetoclax-involved groups and Caspase-3 showed more proteins with 






Figure 17. PLCs and signalling molecules were analyzed in MOLM-13 cells 
after treatment with Azacitidine and/or Venetoclax for 24h. A relative mRNA 
expression of PLCs and PKCα was analyzed by real-time PCR. B Apoptosis 
molecules and signaling proteins were analyzed by Western blot. Significance 
was obtained after multiple student’s t-test comparison. * = p-value < 0.05, ** = 
p-value < 0.01, ***= p-value < 0.001, **** = p-value < 0.0001. 
In HL-60 cells, PLC-β1 showed an increase in Azacitidine-alone treated group, 
while PLC-γ1 showed no significant difference in all groups. On the contrary, 
PKCα showed a gradually decrease trend in all treated groups, with the lowest 
expression in the combined treatment group. p-Akt expression seems to be the 
same for all the treated groups and increased as compared with the control 
group. BCL-2 expression decreased in Venetoclax-involved treatment groups. 
Caspase-3 showed a cleavage in Venetoclax-involved treatment groups 
(Figure 18). 
 
Figure 18. PLCs and signalling molecules were analyzed in HL-60 cells after 
treatment with Azacitidine and/or Venetoclax for 24h. A relative mRNA 
expression of PLCs and PKCα was analyzed by real-time PCR. B Apoptosis 
molecules and signaling proteins were analyzed by Western blot. Significance 
was obtained after multiple student’s t-test comparison. * = p-value < 0.05, ** = 
p-value < 0.01, ***= p-value < 0.001, **** = p-value < 0.0001. 





while PLC-γ1 showed a slight reduction in the Azacitidine-alone treated group 
but a slight increase in the combined treatment group. On the other hand, 
PKCα showed a decreased expression in all treated groups, particularly in the 
combined treatment group. p-Akt expression decreases in Azacitidine-alone 
treated group, while the expression of both BCL-2 and Caspase-3 do not show 
no significant differences in all groups (Figure 19). 
     
Figure 19. PLCs and signalling molecules were analyzed on U-937 cells after 
treatement with Azacitidine and/or Venetoclax for 24h. A relative mRNA 
expression of PLCs and PKCα was analyzed by real-time PCR. B Apoptosis 
molecules and signaling proteins were analyzed by Western blot. Significance 
was obtained after multiple student’s t-test comparison. * = p-value < 0.05, ** = 
p-value < 0.01, ***= p-value < 0.001, **** = p-value < 0.0001. 
In THP-1 cells, PLC-β1 gene expression showed a significant increase in the 
combined treatment at gene level while PLC-γ1 showed an increase in 
Venetoclax-involved treatment at protein level. PKCα gene expression showed 
a significant decrease in all treated groups at gene level, although its protein 
expression in Azacitidine-alone treated group increased. p-Akt expression 
seemed to be the same for all groups, BCL-2 showed a decreased expression 
in the combined treatment, whereas no significant difference in Caspase-3 





Figure 20. PLCs and signalling molecules were analyzed on THP-1 cells after 
treatment with Azacitidine and/or Venetoclax for 24h. A relative mRNA 
expression of PLCs and PKCα was analyzed by real-time PCR. B Apoptosis 
molecules and signaling proteins were analyzed by Western blot. Significance 
was obtained after multiple student’s t-test comparison. * = p-value < 0.05, ** = 
p-value < 0.01, ***= p-value < 0.001, **** = p-value < 0.0001. 
5. DISCUSSION 
EH of bone usually occurs in the long tubular bones [7] and it can involve more 
than one bone in up to 25% of cases [3]. So far, multifocal EHs reported in the 
literature present synchronous bone lesions at the presentation of the disease 
[3, 141]. To our best knowledge, we reported the first case of EH with 
multifocal metachronous bone lesions. According to this case, multiple 
metachronous bone lesions of EH seemed to behave like their contiguous 
counterparts: localized pain to the involved bone and a mixed osteolytic and 
sclerotic feature on radiographs [6]. This case shows the possible existence of 
multifocal metachronous EH without producing a fatal outcome. The diagnosis 
of EH remains challenging, particularly in osseous locations, because of its 
atypical histologic features being confused at the spectrum with other 
epithelioid vascular neoplasms such as EHE or epithelioid angiosarcoma [1, 
8]. In the presented case, this patient was misdiagnosed as EHE at the 
beginning. Morphologically, it is difficult to distinguish between EH and EHE, 




show well-defined cell borders and abundant, densely eosinophilic cytoplasm, 
while a mild degree of cytologic atypia can be seen both in EH and EHE [3]. 
However, several recent studies confirmed that the involvement of FOS gene 
in fusion events could be a highly specific driving event in EH [8–10]. After 
investigating the incidence of FOS rearrangements in a large cohort of EH, 
Huang et al. found FOS rearrangements were present in a third of EH across 
different anatomical locations with more prevalence in intra-osseous lesions in 
comparison with lesions in other locations [1] . Members of the FOS family 
dimerize with Jun proteins to form the AP-1 transcription factor complex, which 
plays a pivotal role in cell growth, differentiation and survival [10, 142]. 
Interestingly, FOS is the AP-1 transcription factor and FOSB represents its 
paralogue. Thus, the presence of FOS and FOSB is mutually exclusive [143]. 
Furthermore, a new translocation was identified, as recurrent ZFP36-FOSB 
fusion in a subset of EH with atypical histological features confirmed FOSB 
immunohistochemical expression, as we found in our case [1]. Previous 
studies demonstrated the distinctive gene fusion of WWTR1-CAMTA1 and 
YAP1-TFE3 in EHE, which cannot be identified in other epithelioid vascular 
tumors, providing a strong and objective molecular tool to assist its diagnosis 
and classification [144, 145]. The importance of distinguishing these two 
entities is paramount, as EHE exhibits a much more aggressive clinical course 
with a fatal outcome and a higher incidence of distant metastases [146, 147]. 
EH of bone is characterized by alterations in epithelioid endothelial cells, that 
could stem also from MSC impairment. In turn, MSCs are clinically relevant 
also in other branches of orthopedics, mainly in regenerative medicine, which 
aims to regenerate the tendon tissue length and tension using scaffolds, 
restoring the native function and biomechanics in the shortest possible time, 
while reducing rehabilitation time [148]. As a potential cell source, MSCs are 
widely used as endothelial progenitor cells in regenerative medicine. Indeed, 
MSCs hold a great promise as an option for the treatment of musculoskeletal 
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regeneration, having a high expansion capacity and the potential to 
differentiate along all mesenchymal lineages [149], thus representing a ground 
for biological scaffolds. In the scenario in which nearly 80% of tendon 
surgeries fail due to tendon re-tear phenomenon, biological scaffolds come 
into play to improve the quality of the regenerated tissue and to ensure 
long-term results, thus providing mechanical reinforcement and improving the 
tendon intrinsic healing potential, directly delivering cells and growth factors 
into the lesion site, in order to reduce the lesion gap [150]. 
Biological scaffolds show improved bioactivity over synthetic ones, while on 
the other hand, the synthetic scaffolds are safer, more stable from a 
biomechanical point of view, with lower donor site morbidity. An ideal scaffold 
should combine the best characteristics of both [151–154]. In general, 
biological and synthetic scaffolds are both employed in the clinical practice for 
augmentation of the conventional surgical practice for both tears of rotator cuff 
(RCT) and Achilles tendon ruptures. More clinical studies are performed in 
rotator cuff in comparison to Achilles tendons and biological scaffolds are more 
commonly employed than synthetic ones [155]. Biological scaffolds 
demonstrate either variable results, platelet‐ rich plasma (PRP) -based ones, 
or poor results, such as bovine equine pericardium and some extracellular 
matrix (ECM). PRP-based scaffolds are employed in rotator cuff and SIS and 
equine pericardium in Achilles tendons, while most biological ECMs are largely 
used in both the two types of tendons [156, 157].  
To further investigate molecular aspects, nuclear inositide signaling pathways 
were analyzed. Nuclear PLC-β1 plays an important role in the regulation of 
hematopoietic differentiation, both at a myeloid and an erythroid level. 
Currently, Azacitidine is the first-line clinical drug for both MDS and AML, 
whereas Venetoclax is mainly used for CLL patients with or without 17p 
deletion, who show a favorable outcome in the vast majority of cases. 
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However, due to the low response rates and refractory to these single 
approaches in several patients, the combination of Venetoclax with Azacitidine 
is being tested, with positive clinical results in AML therapy. The molecular 
mechanisms underlying the effect of this combination therapy are still unclear. 
That is why in this study we analyzed the molecular effects of Azacitidine and 
Venetoclax combination on the nuclear inositide-dependent pathways, mainly 
focusing on PLC-β1. 
At first, we studied the effect of Azacitidine and Venetoclax on hematopoietic 
cell lines. As shown in previous studies, AZA induced a time- and 
concentration-dependent inhibitory effect on U-937, HL-60, THP-1, and 
MOLM-13 cell lines [158–160]. As for Venetoclax, the leukemic cell lines 
showed different sensitivity on growth inhibition. In HL-60 and MOLM-13 cells, 
Venetoclax showed a growth inhibition at a dose of 5 μM and 0.05 μM 
respectively, whereas in U-937 cells and THP-1 cells the single dose of 7.5 μM 
was sufficient to cause growth inhibition. We confirmed the IC50 of each cell 
line, suggesting that HL-60 and MOLM-13 cell lines were relatively sensitive to 
Venetoclax while U-937 and THP-1 were Venetoclax-resistant cell lines.  
Then, we studied the combined effect of both drugs. Several combined 
treatments with different concentrations were analyzed. The 
Azacitidine/Venetoclax combination in each cell line offered significant 
advantages in growth inhibition compared to the use of either drug alone. 
As for the cell cycle analyses, HL-60 and MOLM-13 cells were induced to 
apoptosis when treated by Venetoclax and Azacitidine/Venetoclax 
combination, which confirmed that Venetoclax induced a strong cytotoxic 
effect on these cells. In HL-60 cells, cyclin D3 showed a significant reduction 
linked to an arrest in the G0/G1 phase. On the other hand, cyclin B1 shows a 
significant decrease, which corresponded to an arrest of G2/M phase. 
Interestingly, the G0/G1 arrest observed in Azacitidine-alone treated HL-60 
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cells also corresponded to increased expression of CD11, suggesting that 
Azacitidine might induce a differentiation on HL-60 cells. As for U-937 cells, 
increased expression of cyclin D3 and S phase could be observed after 
treatment.  
THP-1 and MOLM-13 cells also showed a slight increased expression of 
CD14, which is a key differentiation marker for monocytes. This may imply that 
the combined treatment could induce the cells to differentiate from monocytes 
to macrophages. On the other hand, HL-60 cells also showed a slight increase 
of CD11 when treated alone with Azacitidine, suggesting that Azacitidine might 
possibly promote HL-60 myeloid differentiation.  
As for the inositide signaling, in our study it seems that the combined treatment 
of Azacitidine and Venetoclax could upregulate the expression of PLCs 
whereas downregulate their downstream PKCα. Interestingly, it has been 
reported that PLC-β1 activity may be necessary for PKCα negative modulation 
in other leukemia cell lines [128]. From literature [158], PKC isozymes become 
mature through three subsequent phosphorylations on their activation loop, 
turn, and hydrophobic motifs, and then they can be activated by second 
messengers such as IP3 and DAG. The activation mechanism by second 
messengers has already been described [159][160]. Moreover, sustained 
activation of PKCs promotes their dephosphorylation and their degradation 
[161]. All this evidence, together with data presented in our study, suggest that 
the combined treatment of Azacitidine and Venetoclax could induce high 
expression of PLC-β1 which, in turn, could lead to sustained activation of 
PKCα and then to its degradation through the generation of second 
messengers. 
As a BCL-2 inhibitor, Venetoclax could trigger and restore apoptosis in tumor 
cells by releasing proapoptotic proteins from BCL-2. In our studies, little 
changes of BCL-2 and Caspase-3 were shown in U-937 and THP-1 cells when 
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induced by Venetoclax, whereas a significant decrease of BCL-2 was 
displayed in Venetoclax-involved treatment of MOLM-13 and HL-60 cells with 
higher expression of cleaved Caspase-3.  
In conclusion, four types of hematopoietic cells were tested here, finding out 
that MOLM-13 and HL-60 cells are Venetoclax-sensitive cells, whereas THP-1 
and U-937 cells are Venetoclax-resistant cells. On the other hand, Azacitidine 
and Venetoclax treatment could induce an increase of the Sub-G0/G1 phase, 
as well as a G0/G1 arrest in MOLM-13 cells and HL-60 cells. At the same time, 
it seems to prolong the S phase in U-937 cells. Moreover, the combination 
therapy was also able to specifically induce myelopoiesis, as MOLM-13 and 
THP-1 cells showed an increased expression of CD14. Furthermore, the 
combined treatment triggers a higher expression of PLC-β1, which activates 
the signaling pathway to degrade the PKCα. All in all, these results hint at an 
additive effect of the cytotoxic effect of Venetoclax alone and the capability of 
Azacitidine to induce cell cycle arrest and myelopoiesis differentiation. Based 
on the data from the present study, in a mixed cell population, the combination 
therapy could selectively induce apoptosis and cell cycle arrest in leukemia 
cells, favoring the myeloid differentiation and restoring normal hematopoiesis. 
Although these are preliminary data that need to be validated by performing 
functional analyses on downstream targets, these findings obtained by 
signaling transduction could still be important to better understand clinical 
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